Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)
NCT04365400Phase 2Terminated
- Sponsor
- Afimmune
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of epeleuton in hypertriglyceridemia and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Afimmune. Primary endpoints: Percent Change in Triglycerides From Baseline at 16 weeks and Change in HbA1c From Baseline at 26 weeks. Started Oct 2020; status: terminated.
02
Drugs
epeleuton
03
Conditions
hypertriglyceridemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04365400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365400.